http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-3085000-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 |
| filingDate | 2018-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4db02ff20699fe329c239aa7e575bdb0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c671bdc4d6f21f90a4375c311418681a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6f55e1a525f13b8d1f7848d1664149f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6becbcabfefbffc8f85c29bceb7ef527 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_052ca669e0c33377888e6bc014fdeb91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e40491d32a905344a409a4dea4abb094 |
| publicationDate | 2019-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-3085000-A1 |
| titleOfInvention | Method of treating idiopathic thrombocytopenia purpura (itp) with romiplostim |
| abstract | The present invention concerns a method of treating idiopathic thrombocytopenia purpura (ITP) in a patient having ITP, which comprises: (a) administering romiplostim weekly to the patient; (b) increasing the weekly dose until a platelet count of at least about 50 to 200 x 109/L is reached; (c) decreasing the weekly dose of romiplostim if the platelet count remains = 200 x 109/L for two consecutive weeks; (d) discontinuing romiplostim if the platelet count has remained = 200 x 109/L for two consecutive weeks when the weekly dose is 1 µg/kg or the platelet count is = 400 x 109/L; and (e) if a platelet count = 200 x 109/L is reached within the first 4 to 12 weeks of treatment, maintaining a treatment-free period of at least about 24 weeks during which the patient receives no romiplostim. |
| priorityDate | 2017-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.